Vistagen Regains Full Compliance with Nasdaq Listing Requirements
23 Junho 2023 - 9:30AM
Business Wire
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression and other central nervous system
(CNS) disorders, today announced that, on June 22, 2023, Vistagen
received a letter from the Listing Qualifications Staff of The
Nasdaq Stock Market, LLC (Nasdaq) indicating that Vistagen has
regained full compliance with the minimum $1.00 bid price per share
or greater requirement under Nasdaq Listing Rule 5550(a)(2) for
continued listing on the Nasdaq Capital Market. Vistagen is now in
full compliance with all applicable Nasdaq listing requirements,
and Nasdaq considers the matter closed.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. Vistagen is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available for
treatment of anxiety, depression and multiple CNS disorders.
Vistagen’s pipeline includes six clinical-stage product candidates,
including five investigational agents belonging to a new class of
drugs known as pherines and an oral prodrug of 7-Cl-CYNA, which is
a full antagonist of the glycine site of the N-methyl-D-aspartate
receptor (NMDAR). Pherines, which are administered as nasal sprays,
are designed with an innovative rapid-onset mechanism of action
that activates chemosensory neurons in the nasal passages and
selectively impact key neural circuits in the brain without
requiring systemic uptake or direct activity on CNS neurons.
Vistagen is passionate about transforming mental health care and
redefining what is possible in the treatment of anxiety, depression
and several other CNS disorders. Connect at www.Vistagen.com.
Forward Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws. These
forward-looking statements involve known and unknown risks that are
difficult to predict and include all matters that are not
historical facts. In some cases, you can identify forward-looking
statements by the use of words such as “may,” “could,” “expect,”
“project,” “outlook,” “strategy,” “intend,” “plan,” “seek,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,”
“strive,” “goal,” “continue,” “likely,” “will,” “would” and
variations of these terms and similar expressions, or the negative
of these terms or similar expressions. Such forward-looking
statements are necessarily based upon estimates and assumptions
that, while considered reasonable by Vistagen and its management,
are inherently uncertain. These risks and uncertainties are fully
discussed in the section entitled "Risk Factors" in our most recent
Annual Report on Form 10-K for the year ended March 31, 2022, and
in our most recent Quarterly Report on Form 10-Q for the quarter
and nine months ended December 31, 2022, as well as discussions of
potential risks, uncertainties, and other important factors in our
other filings with the U.S. Securities and Exchange Commission
(SEC). Our SEC filings are available on the SEC’s website at
www.sec.gov. In addition, any forward-looking statements represent
our views only as of the issuance of this release and should not be
relied upon as representing our views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230623968973/en/
Investors: Mark McPartland Senior Vice President, Investor
Relations (650) 577-3606 markmcp@vistagen.com
Media: Nate Hitchings SKDK nhitchings@skdknick.com
Vistagen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024